Aphria Inc (TSX:APHA) Gets the Green Light for Expansion: Should You Buy the Stock?

Aphria Inc (TSX:APHA)(NYSE:APHA has received approval from Health Canada to go ahead with its planned expansion. Time to buy?

edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

If any Canadian marijuana producer has had a wild ride over the past year, it would have to be Aphria (TSX:APHA)(NYSE:APHA). After a fourth quarter of 2018 that included short attacks, lawsuits, and a hostile takeover bid, the company entered 2019 with a major management shakeup that fundamentally transformed the company.

For months afterward, it was all quiet on the Aphria front. But now, the company is back in the news with an announcement that it has received clearance from Health Canada to pursue a major expansion project. This news is a signal that Aphria could be gearing up for even more growth after increasing revenue 154% year over year in its most recent quarter. To understand why this news is so big, we need to take a look at what exactly Health Canada approved.

Health Canada approves expansion

For marijuana growers, nothing is more important than production space. The ability to meet the growing demand for cannabis in this country requires significant grow space, and so far, the cannabis growers don’t have enough of it. As a result, the post legalization era has been marked by major supply shortages.

For Aphria, that may be about to change. Earlier this month, Health Canada approved an 800,000-square-foot expansion to the Aphria One grow space in Leamington. This new space will have the capacity to produce 110,000 kg of marijuana a year for about $800 million in revenue at the current cannabis selling price.

$1 billion in revenue predicted

Partially as a result of the recent expansion, Aphria is now forecasting $1 billion in revenue by the end of 2020. The math behind this makes sense given the figures above: the space the company is adding will be able to generate $800 million a year, and that’s on top of the company’s existing space, which drove about $13 million in sales in the most recent quarter. This would represent phenomenal revenue growth, the only question being whether demand for cannabis will be strong enough to justify it.

Takeover seems unlikely

A final point about Aphria is worth mentioning — this one pertaining to the much-discussed hostile takeover bid from Green Growth Brands.

Thanks to all the good news coming from Aphria, it seems unlikely that the Green Growth bid will go through. The all-stock bid valued Aphria at about $9, but with the company’s meteoric growth, its stock has risen to $13 so far this year. Assuming this price level holds, Aphria will be well out of Green Growth’s reach. This is good news for Aphria shareholders, since it means they won’t be forced to exchange each of their shares for 1.5 shares in a much less proven enterprise. This, combined with the recently approved expansion, indicates that this once maligned company may have a bright future ahead of it.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Button has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »